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A rat animal model was used for comparing the
photodynamic efficacy of two formulations of topically
administered Photofrin in the uterus: 0.7 mg/kg Photofrin
and 0.7 mg/kg Photofrin + 4% Azone, a penetration-
enhancing agent. Uterine structure and reproductive
performance were evaluated following illumination with 80
J/cm2 of 630 nm light. Fluorescence microscopy was
employed to determine drug localization in frozen uterine
sections at various times after drug administration.
Functionality studies demonstrated a significant reduction in
the number of implantations per treated uterine horn
compared to controls. The mean number of implantations
decreased systematically on increasing the interval between
Photofrin administration and light application. At 72 h, 0.88
± 0.52 gestational sacs per rat were recorded with Photofrin
therapy, compared with 8.1 ± 1.12 (P = 0.01) on the
untreated side, indicating nearly complete loss of reproductive
capability. Similar results were achieved after only 3 h
treatment with Photofrin+Azone (0.38 ± 0.26 sacs per rat
versus 7.5 ± 1.07 on the untreated side; P = 0.01). This
indicates that the effect of Photofrin can be enhanced either
by extending the drug incubation period from 3 to 72 h or
by adding the penetration-enhancing drug Azone.
Fluorescence pharmacokinetic studies suggest that both forms
of topically administered Photofrin are diffusely distributed
throughout the endometrium at virtually the same rate.
However, Azone may enhance the selectivity of photodynamic
therapy by facilitating drug targeting to critical endometrial
structures.
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Introduction
Photodynamic therapy (PDT) is an investigational technique
which has been applied to human tumours since the mid-1970s
(Dougherty etal., 1975; Kelly and Snell, 1976). PDT applications
have expanded over the years to include a variety of tumours
and hyperplastic diseases. Although the precise mechanism of
photodynamic destruction has not been determined in vivo, several
important features have been identified which have contributed
to the rapid growth of PDT.
In general, the process involves i.v. administration of a
photosensitizing drug that is retained in well-vascularized tissues.
Tissue damage occurs when light of sufficient energy and
appropriate wavelength interacts with the sensitizer, leading to
the generation of highly reactive oxygen intermediates (Weishaupt
et al., 1976; Kimel et al., 1989). These intermediates, primarily
singlet molecular oxygen, irreversibly oxidize essential cellular
components. Ultimately, selective tissue necrosis is observed in
photosensitizer-containing structures (Kreimer-Birnbaum, 1989).
The human endometrium, which has unique proliferation and
neovascularization characteristics, may be ideally suited to PDT.
For example, PDT can provide a novel, selective means for
studying endometrial physiology, particularly regeneration
mechanisms. Endometrial tissue, depending on hormonal status,
can vary between 2 and 9 mm in thickness (Gonen et al., 1989).
Thus, uterine light penetration can be modulated by manipulating
the hormonal state. In addition, the substantial effect PDT has
on tissue microvasculature (Star et al., 1986; Chaudhuri et al.,
1987; Nelson et al., 1988) suggests that it could be highly
effective in the well-vascularized endometrium. Finally, from the
structural standpoint, the thick myometrium surrounding the thin
endometrial layer can serve as a 'barrier' to protect vital pelvic
organs during illumination.
Several groups have studied the distribution of photosensitizers
in rat (Schneider et al., 1988; Chapman et al., 1993; Yang et al.,
1993) and rabbit endometrium (Judd et al., 1992; Bhatta et al.,
1992). Promising results have also been reported for the use of
PDT to diagnose and treat surgically induced endometriosis in
rabbits (Manyak et al., 1989; Petrucco et al., 1990; Vancaillie
et al., 1989). We anticipate that the primary clinical application
of uterine PDT will be photodynamic treatment of dysfunctional
uterine bleeding. In contrast to conventional tumour PDT,
endometrial destruction has less stringent requirements for
optimizing drug concentrations in target compared with normal
tissue. Provided there is sufficient photosensitizer in critical
cellular locations, depth of destruction is limited by our ability
to deliver an effective photodynamic light dose throughout the
endometrium. In general, higher tissue drug concentrations
reduce light dose requirements. As a result, it is beneficial to
increase endometrial drug concentration to the highest possible
value. This can be most effectively accomplished by employing
topical, rather than systemic, drug delivery schemes. An
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additional benefit of topical application is that, unlike conventional
i.v. administration, intra-uterine drug delivery does not result
in cutaneous sensitivity. This is a particularly important
consideration in managing patients with non-life-threatening
conditions.
In previous work, we evaluated the uptake and distribution of
Photofrin (Quadra Logic Technologies, Vancouver, B.C.,
Canada) in uterine tissue following i.v., i.p. and intra-uterine
application in rats (Chapman et al., 1993). Our conclusions were
that topical intra-uterine application offers several advantages in
terms of simplicity, preferential localization and minimal
cutaneous toxicity (Dougherty, 1986). However, intra-uterine
Photofrin administration results in disproportionately high drug
concentrations in the superficial columnar epithelium and
relatively slow drug diffusion in deeper endometrial layers.
Because of this observation, the current study was designed
to evaluate the therapeutic potential of Photofrin-based PDT in
the rat uterus. Particular attention was paid to enhancing the
distribution and photodynamic efficacy of topically administered
Photofrin by adding Azone, a penetration-enhancing agent (Chow
et al., 1984). Fluorescence microscopy of frozen sections was
used to determine Photofrin localization in uterine tissue at various
times after drug application. Photodynamic efficacy was
determined by evaluating uterine structure and reproductive
performance following intra-uterine irradiation with 80 J/cm2 of
630 nm light.
Materials and methods
Animals
A batch of 124 mature female Sprague—Dawley rats weighing
270-325 g were placed in control day/night settings of 12 h each.
The oestrous cycle was monitored by obtaining vaginal smears.
On the day of di-oestrous, the drugs were applied topically by
the intra-uterine route via laparotomy as described previously
(Chapman et al, 1993).
Pharmacokinetic study
Photofrin (Porfimer sodium; Quadra Logic Technologies,
Vancouver, B.C., Canada) was stored as freeze-dried powder
in the dark at 4°C until mixed with sterile water for injection.
A volume of 0.15 ml at a dose of 0.7 mg/kg was administered.
Azone (l-dodecylazacycloheptane-2-one; Whitby Research, Inc.
Richmond, VA, USA) has been used in the past to increase
haematoporphyrin derivative (HPD) penetrance in normal skin
(Chow et al., 1984). It is a clear colourless liquid that is mixed
with Photofrin to make a 4% Azone solution. In all, 36 rats
received intra-uterine Photofrin and 32 received an identical dose
of Photofrin+Azone (0.7 mg/kg). Both uterine horns were
treated.
Animals were killed and the uteri removed for fluorescence
microscopy at different time intervals (0.5, 1.5, 3, 6 and 12 h)
following drug administration. Data were obtained from three
rats at each time point, and one group without any drug was
assigned as a control to determine background autofluorescence
levels. Three uterine specimens 3 - 4 mm thick were placed in
moulds containing embedding medium for frozen sections (OCT
media, Miles, Elkhart, IN, USA). The blocks were rapidly frozen
on dry ice and stored at -70°C in the dark. Tissue sections,
6 i*m thick, were prepared in low diffuse light (Cryostat
microtome; AO Reichert, Buffalo, NY, USA).
Fluorescence microscopy
Low-light-level fluorescence imaging was performed with a slow
scan, thermoelectrically cooled, charged coupled device camera
system (Princeton Instruments, Trenton, NJ, USA) coupled to
a Zeiss Axiovert 10 inverted fluorescence microscope (Carl Zeiss
Inc., Germany). A X10 objective (Zeiss Plan-neofluar, numerical
aperture = 0.3) was used to visualize bright-field and
fluorescence images of frozen sections. A 100 W mercury arc
lamp filtered through a 405 nm bandpass filter (20 nm band width)
provided excitation light. A dichroic filter (Zeiss, FT 420) was
used to separate excitation from emission signals; and a 635 nm
broad bandpass filter (55 nm band width) was used to isolate
the fluorescence emission.
Instrument control, image acquisition and processing were
performed with a Macintosh Ilfx computer and IPlab software
(Signal Analytics Corp., Vienna, VA, USA). Sample photo-
degradation was minimized in bright-field and fluorescence
respectively by firstly locating the region of interest under low,
orange/red light illumination, and secondly by limiting arc-lamp
exposure to 1 — 2 s by electronically synchronizing camera and
lamp shutters. In order to estimate light distribution, background
images were acquired from blank slides under conditions identical
to those used for sample measurements. Dark noise levels were
determined by acquiring images without source illumination. All
fluorescence images were normalized by the following algorithm
in order to correct for dark noise and non-uniform illumination:
Normalized
fluorescence image
Mean (background-dark noise)
x Image
Image (background-dark no i se ) < f l u o l e s ^ I l c e _ d l l l k n o i s e )
where mean (background—dark noise) is the mean grey-scale
value for the dark-noise-corrected background image.
Cross-sectional images of the rat uterus were divided into two
structurally distinct layers for comparative analysis: endometrium
and circular muscle.
Reproductive performance
The second phase of this study was designed to evaluate firstly
the effect of PDT on embryo implantation, and secondly whether
there is a relationship between drug uptake (as demonstrated by
the fluorescence study) and photochemical damage following light
application. In all, 24 rats received Photofrin alone and eight rats
received Photofrin+Azone. The drugs were administered to one
(left) uterine horn in the same mode, volume and concentration
as in the first phase. The 'drug-light' interval in the Photofrin-
treated animals was 3, 24 and 72 h (eight animals each) and in
the Photofrin+Azone group only 3 h. Prior to light treatment,
the rats were re-anaesthetized and the left horns carefully exposed.
A few millimeters distal to the uterine bifurcation, the uterine
wall was punctured with a 20G needle to drain the cavity of traces
of remaining fluid and allow passage of the diffusing fibre.
The light source was an argon-pumped dye laser tuned to emit
630 nm radiation (Spectra Physics, Mountain View, CA, USA).
A clinical Hartridge Reversion spectroscope (Ealing Electro-
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Fig. 1. Fluorescence microscopy curve for Photofrin (left) and Photofrin+Azone (right). Log fluorescence is reported in arbitrary units, as
a function of time, for endometrium (excluding columnar epithelium) and myometrium.
Optics, South Natick, MA, USA) was used to verify the
wavelength to ± 1 nm. The laser beam was transmitted into the
uterine cavity via a fibre with a 2.0 cm long cylindrical diffusing
tip (Model 4420-A02, 400 micron core; PDT Systems, Buellton,
CA, USA). By using a fibre splitter (model 1220; Laser
Therapeutics Inc., Buellton, CA) connected to the laser source
by a 200 /tm core fibre (model 52120-A05; PDT Systems), two
to three animals could be treated simultaneously. All animals
received a total illumination dose of 80 J/cm2 at a power density
of 100 mW/cm2. Before, during and after treatment the uterine
horn was moistened with saline to prevent drying. At the end
of the laser treatment, the abdominal wall was closed with Dexon
4—0 and the skin secured with staples. Recovery was monitored
until return of normal activity. The rats were housed individually
with free access to food and water.
In order to assess reproductive performance, rats were bred
with mature male Sprague—Dawley rats between 21 and 28 days
after PDT. Female rats were killed in the second or third trimester
of pregnancy and the entire genital tract was excised and fixed
in 10% buffered formalin after photo-documentation. The location
and number of nidations were noted for each uterine horn.
Specimens of the treated uterine horns were sectioned and stained
with haematoxylin and eosin for histological evaluation. Control
groups consisted of animals that received photosensitizer without
laser irradiation (Photofrin, eight rats; Photofrin+Azone, six rats)
and six animals that were treated with laser light and no drug.
Skin photosensitivity
All animals in the study group received a 100 J/cm2 light dose
(200 mW/cm2) on a 1 cm2 shaved area of the upper right
abdomen. Light was delivered, as above, from a microlens-
terminated, 400 /jm diameter, fused silica fibre coupled to an
argon-pumped dye laser (model 316; Spectra-Physics). The
treated skin was checked immediately after light application,
during recovery, and daily until the end of the study.
Statistical analysis
The number of gestational sacs in the treated and untreated areas
was analysed with a paired two-tailed r-test and paired Wilcoxon
signed rank test. Implantations with different therapeutic
modalities were analysed using the Kruskal -Wallis test and the
Mann—Whitney CZ-test. Results were considered to be statistically
significant at P < 0.05. Cited results refer to the Wilcoxon signed
rank test and the Mann—Whitney U-test respectively.
Results
Pharmacokinetic study
Figure 1 summarizes the results of frozen-section fluorescence
microscopy studies for Photofrin (Figure la) and Photofrin+
Azone (Figure lb). Log fluorescence is reported in arbitrary
units, as a function of time, for endometrium (excluding columnar
epithelium) and myometrium. Each time-point represents average
values for three animals, with the following exceptions: two
animals at time-points 0.5 and 3 h in the Photofrin and
Photofrin+Azone groups respectively, and four animals at time-
points 6 and 12 h in the Photofrin+Azone group. The results
indicated there was a sharp increase in drug uptake for
endometrial and myometrial layers within the first 90 min of
topical application. Fluorescence levels were higher for endo-
metrium than for myometrium at early time-points, particularly
in the case of Photofrin+Azone (Figure lb). However, these
values eventually converged and fluorescence remained elevated
for both drugs at 12 h.
These observations were supported by representative frozen-
section images of tissue treated with Photofrin+Azone (1.5 h
post-injection), as shown in Figure 2. Examination of bright-field
(Figure 2a) and fluorescent (Figure 2b) micrographs clearly
showed the previously observed intense columnar epithelial
fluorescence (Chapman et al., 1993). In contrast, endometrial
and myometrial fluorescence levels were substantially lower.
However, as indicated in Figure 1, endometrium appeared to be
brighter than the surrounding myometrium. Although Photofrin
tissue distribution is not shown, the results were generally similar
to Figure 2.
Reproductive performance following PDT
Figure 3 shows that, in all study groups, there was a significant
difference between the number of implantations per rat in the
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Fig. 2. Bright-field image (a) and fluorescence micrograph (b) of the rat uterus at 1.5 h following topical application of Photofrin with
Azone. CE = columnar epithelial fluorescence.
treated left uterine horn compared with the corresponding,
untreated control right side (P < 0.05). A more effective outcome
with Photofrin as a single agent was obtained by extending the
time interval between the drug administration and the light
application to 72 h. In the case of Photofrin, the mean number
of gestational sacs per uterine horn was 2.38. The mean ±SE
was 2.38 ± 0.92 in the treated side and 5.12 ± 0.74 in the
control side (P = 0.04) at 3 h. The 24 h interval resulted in 1.5
± 0.68 implantation sites for the left side and 5.9 ± 0.88 for
the control (P = 0.02); at 72 h the corresponding values were
0.88 ± 0.52 compared with 8.1 ± 1.12 (P = 0.01). The
difference between 3 and 72 h was significant (P < 0.02).
In the case of Photofrin+Azone, the mean ± SE number of
gestational sacs per treated area was 0.38 ± 0.26 in the treated
side and 7.5 ± 1.07 in the untreated side (P = 0.01). The
Photofrin+Azone combination was more effective than Photofrin
alone in the short (3 h) interval (P = 0.02). No significant
difference was observed between the number of implantations
per treated horn for 3 h Photofrin+Azone and 72 h Photofrin.
Figure 4 clearly shows the impact of PDT on reproductive
performance. Multiple gestational sacs were visible in the control
horn and one sac appeared in the distal end of the
photodynamically treated left horn. The single pregnancy in the
treated side (Photofrin+Azone, 3 h) was located in an area that
was exposed to a reduced light intensity. This artefact of fibre
geometry and placement was presumed to result in the delivery
of a sub-threshold light dose for irreversible photodynamic
damage.
In the diree control groups (two drug combinations with no
light and light without drug), there was a tendency for fewer
implantations in the manipulated horn, though the difference was
not statistically significant. PDT was tolerated well by all rats.
No signs of any adverse effects were noticed during treatment,
recovery, or the subsequent pregnancy.
Morphological changes after PDT
Immediately following light application there was a blanching
effect of the treated area. By 6—8 weeks later the treated left
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Fig. 3. Number of gestational sacs implanted in the treated area of
the left uterine horns (solid bars) and the corresponding, untreated
control right sides (hatched bars).
Fig. 4. Rat uterus with multiple gestational sacs in the control horn
and a single sac in the distal end of the left uterine horn, which
received photodynamic therapy (PDT). A = PDT horn, B =
control horn, C = cervix.
uterine horn of most animals showed signs of atrophy, with
various degrees of decreased diameter. Two animals in the
Photofrin+Azone group with marked atrophy had pseudo-cystic
Reproductive performance in rats after PDT
Fig. 5. Cross-sections of rat uterus (haematoxylin and eosin stained, x 10). (a) 72 h interval between Photofrin and light, the rat having
been killed 5.5 weeks post-photodynamic therapy (PDT). Endometrial stroma is destroyed on the right side of the specimen. On the left
side, the endometrium is well-stimulated, indicating insufficient damage (arrows), (b) 3 h interval between the administration of
Photofrin+Azone and illumination, the rat having been killed 7 weeks post-PDT. This treatment resulted in destruction of the entire
endometrium, it being replaced by scar tissue. S = scar tissue, L = longitudinal muscle, C = circular muscle, M = mesometrium.
dilatation of the distal part of the uterine horn. No morphological
changes were detected in the controls. Taking into consideration
the time-consuming manipulations of the left uterine horn during
treatment, we found surprisingly few adhesions of any clinical
significance. Even the peritoneal serosa covering the treated
region of the uterus was smooth and unchanged. However, at
the site of fibre insertion into the uterus, there were some forms
of mild filmy adhesions in 86% of the PDT animals and the laser
controls. No uterine perforation was observed.
Skin photosensitivity
Skin photosensitivity was not observed in any of the treated
animals at any time during follow-up.
Structural damage
In order to determine the extent of structural damage, we
examined rat uteri from each group several weeks after PDT.
Figure 5 shows haematoxylin/eosin-stained sections (X 10) for
72 h Photofrin (Figure 5a) and 3 h Photofrin+Azone (Figure
5b) at 5.5 and 7 weeks post-PDT respectively. The endometrium
was destroyed on the right side of the specimen in Figure 5a,
as indicated by the arrows. Only columnar epithelium was left,
along with the circular and longitudinal muscle layer and
peritoneal serosa. On the left side the endometrium was well
stimulated, indicating insufficient damage. Uneven damage was
occasionally observed, regardless of time-point, and may have
been the result of inhomogeneous light delivery to the tissue. In
Figure 5b, Photofrin+Azone treatment resulted in destruction
of the entire endometrial stroma. There was substantial scar tissue
formation which effectively replaced the lumen.
Discussion
The limited information available on the use of PDT for selective
endometrial ablation is based mainly on systemic Photofrin studies
(Schneider et al., 1988; Chapman et al., 1993). In our estimation,
the most likely candidates for uterine PDT are women with benign
endometrial disorders leading to dysfunctional uterine bleeding.
In order to treat these cases successfully, drug concentrations
should be as high as possible throughout the endometrium. For
a given optical dose (provided it is above a threshold value), high
drug concentrations permit damage to greater depths, an
important requirement for complete destruction of the endometrial
zone. In order to achieve comparable effective drug concen-
trations using i.v. administration, patients would be subjected
to the unacceptable risk of skin photosensitivity, which is the main
side-effect for PDT and a limiting factor for its clinical
application. As a result, we have investigated topical
administration strategies for photodynamic destruction of
endometrial tissue.
In previous work (Chapman et al, 1993), we demonstrated
that intra-uterine administration of Photofrin is feasible; however,
it resulted in relatively high uptake and retention by the superficial
columnar epithelium, and slow penetration to deeper uterine
layers. In this study, we attempted to expand our earlier findings
by improving Photofrin tissue distribution and photodynamic
efficacy with Azone, a penetration-enhancing agent. Azone has
been used with both hydrophobic and hydrophilic molecules.
Optimum concentration can vary, but 1-5% Azone solutions
appear to be appropriate for most formulations (Chow et al.,
1984).
Pharmacokinetic studies of the two drug formulations
(Figure 1) showed similar fluorescence patterns. There was a
rapid rise in fluorescence, followed by a plateau at about 1.5 - 3
h, during which maximum contrast between endometrial stroma
and circular myometrium was observed. Drug levels persisted
for the entire 12 h observation period. Examination of Figure
lb indicates that the Photofrin+Azone combination may have
had slightly greater endometrial selectivity. Overall, the
pharmacokinetics and structural distribution were quite similar
for7 both formulations. These findings are clearly illustrated in
the frozen-section images (Figure 2). In addition, this figure
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shows that the columnar epithelium does not appear to inhibit
Photofrin+Azone diffusion substantially.
Nevertheless, due to the extremely high columnar epithelium
fluorescence, it was difficult to determine the precise impact of
Azone on Photofrin penetrance. Fluorescence microscopy-based
pharmacokinetic studies provide visual evidence of drug
localization but are not necessarily predictive of structural damage
during PDT. This is particularly true for Photofrin, since it is
a mixture of compounds which vary in photodynamic efficacy,
subcellular localization and fluorescence quantum yield. In
addition, Photofrin's most photoactive components are probably
least fluorescent. Ultimately, photo-damage is a consequence of
drug association with oxidizable molecules and critical structures
in cells and organelles. This information is difficult to infer from
frozen-section fluorescence micrographs.
The reproductive performance study, illustrated in Figures 3
and 4, is a better indicator of functional photodynamic damage.
These results show that the number of implantations per treated
area was significantly reduced in all treated uterine horns.
Substantially impaired reproductive performance was demon-
strated for Photofrin PDT at all time-points (drug—light intervals:
3, 24 and 72 h), as well as for 3 h Photofrin+Azone. However,
implantations decreased significantly when the Photofrin
drug—light interval was increased from 3 to 72 h, indicating that
treatment efficacy increased with incubation time. Interestingly,
72 h Photofrin results were comparable to those obtained for
animals in the 3 h Photofrin+Azone group. These observations
suggest that the primary consequence of combining Photofrin with
Azone may be to enhance the localization of 'active' Photofrin
components in essential, oxidizable cellular structures. Without
Azone, the systemic contribution of residual recirculating
Photofrin at 72 h may play a role in enhancing efficacy. In
addition, Photofrin fluorescence at 24 and 72 h may be derived
from more photodynamically active components (compared to
3 h), since the spatial distribution of fluorescence appears to be
the same for both formulations regardless of time.
Evaluation of long-term structural effects shows similar damage
patterns for 3 h Photofrin+Azone and 72 h Photofrin.
Endometrial stroma was clearly destroyed using both
formulations. Only columnar epithelium, muscle and peritoneal
serosa remained post-irradiation. Both formulations resulted in
substantial scar tissue formation which, in the case of
Photofrin+Azone, replaced the lumen. However, our occasional
observation of uneven damage, regardless of time-point,
underscores the importance of uniform light delivery.
Endometrium can easily regenerate if the photodynamic damage
threshold of the tissue is not exceeded. Regenerating tissue can
originate in a single location and eventually proliferate throughout
the entire uterine cavity. This observation is further confirmed
by pregnancy study results using 2 cm long diffusing fibre tips.
Since the uteri were somewhat longer than 2 cm, regions proximal
and/or distal to the tip were exposed to light at a reduced intensity
(Figure 4). These areas of sub-threshold irradiation exhibited
more pregnancies as compared with the fully irradiated uterine
regions.
We conclude that the penetration-enhancing drug Azone can
be used to modulate the efficacy of topically applied Photofrin
during uterine PDT. The mechanism of action is not clear solely
from the results of fluorescence-imaging, pharmacokinetic
studies. However, when these observations are considered in
conjunction with tissue histology and post-irradiation pregnancy
tests, we surmise that Azone facilitates the delivery of photoactive
Photofrin components to critical cellular structures. Combining
Photofrin with Azone may be of practical use since it seems to
permit earlier treatment following topical administration of the
drug. The use of effective, topical sensitizers is desirable due
to the fact that they involve relatively low doses and do not cause
skin photosensitivity. However, selectivity and tissue damage
must be carefully evaluated using topical applications, since drug
localization mechanisms and photodynamic targets are probably
different from those associated with i.v. administration strategies.
In order to optimize topical endometrial PDT it is therefore
essential to evaluate several factors. In the case of human
applications, where large, irregularly shaped uterine cavities are
encountered, particular attention should be paid to drug and light
distribution in the tissue. Uterine tissue optical properties should
be determined in order to design delivery systems which can
uniformly illuminate the entire cavity. Adequate illumination
should result in light levels that are above the threshold
photodynamic dose for a given drug. Finally, animal model
studies designed to measure a functional endpoint, such as the
contraceptive effect of PDT, should be used to compare different
photosensitizers. These issues must be considered in order to
ensure a long-term effect in human tissue.
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